RE:RE:RE:RE:RE:RE:RE:RE:Q&A indicates LSA has brought some good new investorsI am very surprised to read that, especially coming from you. You lost it totally over the last financing, because in your view they gave away value you partly owned, and now you would be open to give away even more value to an opportunistic partner? My view on this is that the are competent, they know what they do, and the day they will come out with very positive hard data on humans, the SP wil explode, and than they will be able to bring a lot of cash in at very favourable terms, and money allows to do a lot of things, you can attract more competent people, and you can speed up the process. As I wrote in my previous message, I would be willing to partner with companies owning proprietary cancer drugs, but I would keep all that can be done with generic drugs or isotopes. That's the potential beauty of this peptide, it can lead to multiple NMEs. Partner the proprietary stuff you could not access otherwise until it becomes generic, and keep full rights to all the generic related possibilities.
SPCEO1 wrote: Paul touched on many of the things you have spoken about in the slide belwo and they clearly are not lacking in imaginination about the possibilities. But is this something a small company like TH can handle on their own? Beliveau and Marsolais seem impressive to us but given the size of this thing, should they be quick to partner at least some aspects of this opportunity versus holding things back due to a lack of resources?